Pfizer Inc PFE

$29.45 -0.35 (-1.17%)

Valuation

Market cap
169,793,280,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.85
Forward PE
10.20
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
27,260,376
Avg volume
32,030,959
Day's range
$29.22 – $29.82
Shares out
5,699,674,000
Stochastic %K
46%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Cedenmo Oct 28, 8:26 PM
$PFE while I bought this for a bigger pop because of its sector, the yield on it is pretty good for reinvesting dividends at a cheaper price. I hit the jackpot with MO over the past 5-6 years of owning it because of that (9-10% vs 6-7% with PFE).
0 replies
PFElinepfrenzy1990 Oct 28, 8:11 PM 2 replies
nimii Oct 28, 7:29 PM
$PFE 😡
1 replies
umiak1 Oct 28, 6:53 PM
$PFE HER2-positive is a tough nut to crack. This is truly wonderful news. “The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc.’s (NYSE:PFE) TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab. This regimen serves as a maintenance therapy for adults battling unresectable locally advanced or metastatic HER2-positive breast cancer following their initial induction treatment. This regulatory decision stems from the robust HER2CLIMB-05 Phase 3 trial. Patients receiving the TUKYSA combination experienced a 35.9% reduction in the risk of disease progression or death compared to those taking a placebo alongside trastuzumab and pertuzumab.”
1 replies
Outcomes Oct 28, 6:18 PM
$IBRX $PDSB $MRNA $MRK $PFE https://x.com/fa21519230/status/2115488718928634260?s=46
0 replies
stockjusthave Oct 28, 4:45 PM
$PFE As usual crawling up few days by 1 percent or less and then crawling down for few days, ER up by 2-3% and then crawl down. Then the same cycle...
0 replies
goguryo2000 Oct 28, 4:37 PM
$PFE Same tactic. Scare away the small people before the ER. ER will be a kick ass, even bigger this time and you know why. One thing that I am focusing to follow is that lyme disease vaccine. Yeah, it is already approved by FDA back in early this year. Is this in the market yet? This, I think is huge + for PFE. GLTL. Will see you above 30s soon again.
2 replies
Cogsey Oct 28, 4:35 PM
$PFE crashing through earnings
0 replies